Drug intelligence / Profile preview

N-benzyl-4-[(2R)-pyrrolidin-2-ylmethoxy]aniline

Development stage: Unknown
Modality: Small Molecules

Overview

N-benzyl-4-[(2R)-pyrrolidin-2-ylmethoxy]aniline is an experimental small molecule compound with the molecular formula C18H22N2O and a molecular weight of approximately 282.38 g/mol. It acts as an inhibitor of leukotriene A4 hydrolase, an enzyme involved in the biosynthesis of leukotriene B4, which plays a role in inflammatory processes. The compound has not been approved for clinical use and there are no registered clinical trials or marketed products containing this molecule[1][2][3]. Its primary mechanism is believed to be anti-inflammatory through inhibition of leukotriene A4 hydrolase[2].

Other names: N-benzyl-4-(pyrrolidin-2-ylmethoxy)anilineN-Benzyl-4-(2-pyrrolidinylmethoxy)aniline

Targets

LTA4H (Leukotriene A4 hydrolase)

Beyond the preview

Go deeper on N-benzyl-4-[(2R)-pyrrolidin-2-ylmethoxy]aniline.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on N-benzyl-4-[(2R)-pyrrolidin-2-ylmethoxy]aniline.

Explore the full profile